Novel approaches to immunotherapy for B-cell malignancies.
Immunotherapy for cancer refers to a wide array of novel therapeutic interventions that harness the immune system to target and eradicate malignant cells in the host. Advances in the understanding of how tumor cells evade host immune detection, coupled with improved gene transduction technologies, have enabled investigators to propose and test novel immune-based therapies for B-cell malignancies. As a result, more immunogenic vaccination strategies, able to elicit immune responses to otherwise poorly immunogenic tumor antigens, are being tested in early clinical trials. Furthermore, with the development of efficient T-cell transduction methodologies, investigators are able to generate autologous antitumor T-cell responses through the introduction of chimeric antigen receptors able to target tumor antigens. However, whether the promising preclinical and phase I clinical data presented here will ultimately translate into improved survival of patients with B-cell malignancies remains largely unknown.
Brentjens
Renier J
RJ
Hematology/Oncology Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. brentjer@mskcc.org
D000951:Antigens, Neoplasm / Q000737:chemistry / Q000378:metabolism; D019496:Cancer Vaccines / Q000737:chemistry; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003713:Dendritic Cells; D006801:Humans; D007107:Immune System; D007167:Immunotherapy / Q000379:methods*; D015448:Leukemia, B-Cell / Q000276:immunology* / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000628:therapy*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines